We present the case of an 18-year-old male who was diagnosed at age 15 with extensive ileal and colonic Crohn's disease with rectal involvement and associated perianal fistula. The patient received different treatments with biologics withouth achieving response, so we decide to try combination therapy with subcutaneous Infliximab and Risakizumab. The patient showed improvement at second week, achieving both analytical, clinical and endoscopic response .
View Article and Find Full Text PDFIntroduction: Infliximab (IFX) is effective in treating ulcerative colitis (UC) and in achieving mucosal healing (MH). Little is known about the role of mucosal healing (MH) in the subsequent evolution of the disease and the consequences of discontinuing treatment.
Aims: To evaluate the characteristics and evolution of patients with UC treated with IFX who discontinued treatment after disease remission.